Mounjaro Maker Eli Lilly's Bumper Q2 Earnings Exceeds Estimates, Hikes Outlook Again On Strong Diabetes And Weight Loss Drugs Sales
Portfolio Pulse from Vandana Singh
Eli Lilly (NYSE: LLY) reported strong Q2 earnings, with revenue of $11.3 billion, up 36% YoY, surpassing estimates. The growth was driven by increased sales of diabetes and weight loss drugs, particularly Mounjaro, Zepbound, Verzenio, Taltz, and Jardiance. The company raised its 2024 sales and EPS guidance, reflecting confidence in continued strong performance.
August 08, 2024 | 12:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly reported strong Q2 earnings, with revenue of $11.3 billion, up 36% YoY, driven by increased sales of key drugs. The company raised its 2024 sales and EPS guidance, reflecting confidence in continued strong performance.
Eli Lilly's strong Q2 earnings, driven by significant sales growth in key drugs, and the raised 2024 sales and EPS guidance indicate a positive outlook for the company. The premarket stock price increase of 12.50% reflects investor confidence.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100